Loading…
Loading…
EQUITY / NASDAQ · XNAS
Propanc Biopharma, Inc.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →07/01/2025 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗0.5075 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 0.5075 USD · Volume 72,275
250 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
07/01/2025 – 06/30/2026 · Units
| Metric | 2026 / Year end | 2025 / Year end | Change |
|---|---|---|---|
| Operating profit | -18,185,569 USD | -57,278,131 USD | — |
| Net income | -18,862,710 USD | -58,923,300 USD | — |
| Operating cash flow | -5,682,635 USD | -405,168 USD | — |
| Total liabilities | 3,378,251 USD | 5,725,616 USD | -41.00% |
| Total equity | 9,401,661 USD | 13,906,192 USD | -32.39% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Year end07/01/2025 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 301/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 307/01/2025 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 310/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2026 / Quarter 207/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2026 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Year end07/01/2024 – 06/30/2025ConsolidatedUnits · USD | 2025 / Quarter 306/30/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Capital expendituresCash flow statement | 4,933 USD | — | 4,912 USD | — | 4,758 USD | — | — | — |
| Financing cash flowCash flow statement | 6,457,298 USD | — | 4,473,485 USD | — | 3,491,871 USD | — | 490,756 USD | — |
| Investing cash flowCash flow statement | -4,933 USD | — | -4,912 USD | — | -4,758 USD | — | — | — |
| Net incomeIncome statement | -18,862,710 USD | -6,360,336 USD | -14,289,468 USD | -3,091,394 USD | -7,929,132 USD | -4,837,738 USD | -58,923,300 USD | — |
| Operating cash flowCash flow statement | -5,682,635 USD | — | -4,080,653 USD | — | -2,938,207 USD | — | -405,168 USD | — |
| Operating profitIncome statement | -18,185,569 USD | -6,400,221 USD | -14,728,519 USD | — | -8,328,298 USD | — | -57,278,131 USD | — |
| Total assetsBalance sheet | 12,779,912 USD | 14,333,780 USD | — | — | — | — | 19,631,808 USD | 19,631,808 USD |
| Total equityBalance sheet | 9,401,661 USD | 9,827,885 USD | — | 10,452,265 USD | — | 14,361,167 USD | 13,906,192 USD | 13,906,192 USD |
| Total liabilitiesBalance sheet | 3,378,251 USD | 3,505,895 USD | — | — | — | — | 5,725,616 USD | 5,725,616 USD |
| Report source | Open report ↗ Published: 09/25/2026 | Open report ↗ Published: 05/14/2026 | Open report ↗ Published: 05/14/2026 | Open report ↗ Published: 05/14/2026 | Open report ↗ Published: 02/17/2026 | Open report ↗ Published: 05/14/2026 | Open report ↗ Published: 09/25/2026 | Open report ↗ Published: 05/14/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.